Evidence map›Paper›PMID 27582495›Full record

ArticleThe Journal of biological chemistry2016

Strong Enrichment of Aromatic Residues in Binding Sites from a Charge-neutralized Hyperthermostable Sso7d Scaffold Library.

Michael W Traxlmayr, Jonathan D Kiefer, Raja R Srinivas, Elisabeth Lobner, Alison W Tisdale, Naveen K Mehta, Nicole J Yang, Bruce Tidor, K Dane Wittrup

Open access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
6.0field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 49 citations in OpenAlex.

  1. Article
  2. From sequence to scaffold: Computational design of protein nanoparticle vaccines from AlphaFold2-predicted building blocks.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Both intratumoral regulatory T cell depletion and CTLA-4 antagonism are required for maximum efficacy of anti-CTLA-4 antibodies.Proceedings of the National Academy of Sciences of the United States of America · 2023
    Article
  8. Article
  9. Review
  10. Article
  11. Affinity and Stability Analysis of Yeast Displayed Proteins.Methods in molecular biology (Clifton, N.J.) · 2022
    Article
  12. Article
  13. Targeting the "undruggable" RAS with biologics.Advances in cancer research · 2022
    Review
  14. Article
  15. Review
  16. Article
  17. A conformation-specific ON-switch for controlling CAR T cells with an orally available drug.Proceedings of the National Academy of Sciences of the United States of America · 2020
    Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Michael W TraxlmayrFrom the Koch Institute for Integrative Cancer Research and michael.traxlmayr@boku.ac.at.ORCID http://orcid.org/0000-0002-2108-582X
Jonathan D KieferFrom the Koch Institute for Integrative Cancer Research and.
Raja R SrinivasDepartments of Biological Engineering and.
Elisabeth LobnerDepartment of Chemistry, Division of Biochemistry, BOKU-University of Natural Resources and Life Sciences, 1190 Vienna, Austria.
Alison W TisdaleFrom the Koch Institute for Integrative Cancer Research and.
Naveen K MehtaFrom the Koch Institute for Integrative Cancer Research and.
Nicole J YangFrom the Koch Institute for Integrative Cancer Research and.
Bruce TidorDepartments of Biological Engineering and.
K Dane WittrupFrom the Koch Institute for Integrative Cancer Research and wittrup@mit.edu.
Koch Institute for Integrative Cancer Research At MITBOKU University · ATMassachusetts Institute of Technology · US

Funding

VIRUS PRODUCTION COREP30CA014051 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI MATTHEW G. VANDER HEIDEN · 1985 to 2026
$93.9M
Engineered Antibody EGFR Antagonist Cancer TherapeuticsR01CA096504 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI WITTRUP, KARL DANE · 2002 to 2017
$9.7M
Computational Design of Inhibitor SpecificityR01GM082209 · NIGMS · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI TIDOR, BRUCE · 2009 to 2017
$2.7M
Localizing Immunotherapy to Improve Therapeutic IndexR01CA174795 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI WITTRUP, KARL DANE · 2013 to 2017
$2.0M
Acquisition of Octet Biolayer Interferometry system for MIT biophysics facilityS10OD016326 · OD · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI IMPERIALI, BARBARA · 2014 to 2014
$180k
Austrian Science Fund FWF J 3496Austrian Science Fund FWF W 1224NCI NIH HHS P30 CA014051NCI NIH HHS R01 CA096504NCI NIH HHS R01 CA174795NIGMS NIH HHS R01 GM082209NIH HHS S10 OD016326
6 · The paper itself

Abstract

The Sso7d protein from the hyperthermophilic archaeon Sulfolobus solfataricus is an attractive binding scaffold because of its small size (7 kDa), high thermal stability (T

Indexed as

Hot TemperatureAmino Acids, AromaticAnimalsArchaeal ProteinsBinding SitesDNA-Binding ProteinsHEK293 CellsHumansMiceProtein StabilitySulfolobus solfataricusAmino Acids, AromaticArchaeal ProteinsDNA-Binding ProteinsSso7d protein, Sulfolobusaromatic amino acidsdirected evolutionepidermal growth factor receptor (EGFR)molecular evolutionprotein chargeprotein stabilityscaffold proteinyeast display

Identifiers

PMID27582495
PMCPMC5077188
OpenAlexW2510025743

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.